SEQLL INC. GRANTED SECOND 180-DAY EXTENSION BY NASDAQ REGARDING MINIMUM BID REQUIREMENTS
2022年12月23日 - 6:00AM
SeqLL Inc. (NASDAQ: SQL and SQLLW) (“SeqLL” or the “Company”), a
technology company providing life sciences instrumentation and
research services, announced that on December 20, 2022, the Company
received written notice (the “Notice”) from the Listing
Qualifications Department of The Nasdaq Stock Market LLC
(“Nasdaq”), granting the Company’s request for a 180-day extension
to regain compliance with the Nasdaq’s $1.00 minimum bid price
requirement under Nasdaq Listing Rule 5550(a)(2). If at any time
prior to June 19, 2023, the bid price of the Company's ordinary
shares closes at $1.00 per share or more for a minimum of 10
consecutive business days, the Company will regain compliance with
the Bid Price Rule, and the matter will be closed.
Pursuant to Nasdaq Listing Rule 5810(c)(3)(A),
Nasdaq staff determined that the Company was eligible for an
additional 180 calendar day period, or until June 19, 2023, to
regain compliance based on the Company meeting the continued
listing requirement for the market value of publicly held shares
and all other applicable requirements for initial listing on the
Nasdaq Capital Market, with the exception of the bid price
requirement, and the Company having provided written notice of its
intention to cure the deficiency during the second compliance
period, including by effecting a reverse stock split, if
necessary.
If the Company is not in compliance by June 19,
2023, Nasdaq will provide written notification to the Company that
its ordinary shares will be delisted. At that time, the Company may
appeal the relevant delisting determination to a hearings panel
pursuant to the procedures set forth in the applicable Nasdaq
Listing Rules. However, there can be no assurance that, if the
Company does appeal the delisting determination by Nasdaq to the
hearings panel, that such appeal would be successful.
The Company intends to monitor the closing bid
price of its common shares between now and June 2023 and intends to
consider available options to cure the deficiency and regain
compliance with the minimum bid price requirement within the
compliance period, including possibly a reverse stock split of its
common stock. The Company’s common shares will continue to be
listed and trade on the Nasdaq Capital Market during this period,
unaffected by the receipt of the written notice from Nasdaq.
This announcement is made in compliance with
Nasdaq Listing Rule 5810(b), which requires prompt disclosure of
receipt of a deficiency notification.
About SeqLL Inc.SeqLL is a
technology company providing life sciences instrumentation and
research services in collaborative partnerships aimed at the
development of novel scientific assets and intellectual property
across multiple “omics” fields. The Company leverages its expertise
with its True Single Molecule Sequencing (“tSMS®”) platform to
empower scientists and researchers with improved genetic tools to
better understand the molecular mechanisms of disease that is
essential to the continued development of new breakthroughs in
genomic medicine, and that hopefully address the critical concerns
involved with today’s precision medicine. In sum, our experienced
team works with our collaborators to develop innovative solutions
tailored to the needs of each specific project.
Forward Looking StatementsThis
press release contains certain forward-looking statements,
including those related to the applicability and viability of the
Company’s technology for quantifying RNA molecules from
blood and other statements that are predictive in nature and
those related to regaining compliance with Nasdaq’s continued
listing requirements, and timing and effect thereof.
Forward-looking statements are based on the Company’s current
expectations and assumptions. The Private Securities Litigation
Reform Act of 1995 provides a safe-harbor for forward-looking
statements. These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
“expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,”
“potential,” “predict,” “project,” “should,” “would” and similar
expressions and the negatives of those terms. Prospective investors
are cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this presentation.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Important factors that could cause
actual results to differ materially from those in the
forward-looking statements are set forth in the Company’s filings
with the Securities and Exchange Commission, including its Annual
Report on Form 10-K for the year ended December 31, 2021 under the
caption “Risk Factors.”
Contacts:
John W. KennedyInvestor Relations Tel: +1 (914)
727-7764Email: jwkennedy@seqll.com
SeqLL (NASDAQ:SQLLW)
過去 株価チャート
から 9 2024 まで 10 2024
SeqLL (NASDAQ:SQLLW)
過去 株価チャート
から 10 2023 まで 10 2024